- Home
- DFIN vs IMTX Comparison
DFIN vs IMTX Comparison
Compare DFIN & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DFIN | IMTX |
|---|---|---|
| Founded | 1983 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DFIN | IMTX |
|---|---|---|
| Price | $48.16 | $9.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $61.50 | $19.00 |
| AVG Volume (30 Days) | 199.7K | ★ 539.3K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.72 | N/A |
| Revenue | ★ $963,000,000.00 | N/A |
| Revenue This Year | $4.98 | N/A |
| Revenue Next Year | $3.87 | $25.91 |
| P/E Ratio | $17.76 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $36.11 | $5.29 |
| 52 Week High | $57.23 | $12.41 |
Technical Indicators
Market Signals| Indicator | DFIN | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.47 | 51.09 |
| Support Level | $45.09 | $9.37 |
| Resistance Level | $50.64 | $10.55 |
| Average True Range (ATR) | 1.43 | 0.45 |
| MACD | -0.14 | 0.05 |
| Stochastic Oscillator | 37.61 | 63.92 |
Price Performance
Historical ComparisonAbout DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance software solutions and related services provider. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. It operates in four reportable segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management (its key revenue-generating segment), Investment Companies - Software Solutions, and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States (USA), Europe, Asia, Canada, and Others, of which the USA accounts for the vast majority of its total revenue.
About IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.